Hi-tech ambitions for Fill Finish

“We sense fear of the unknown… yes, the future may appear scary, but the future of our industry needs us to act now.” These are the words of Stefan Merkle, Senior Director Sterility Assurance at Janssen at last year’s Fill Finish Technologies to Reduce Drug Release Times event (FF18). While this comment was in relation to a discussion on whether to pursue in-line monitoring/real-time release (ILM/RTR) technologies, it is equally applicable to the fill finish environment as a whole.

The Fill Finish Phorum has recently embarked on a series of exciting and ambitious initiatives, exploring new technologies and processes to enhance the efficiency and speed of drug release.

 

 

One of the key steps the Phorum has taken was to look at technologies that are already available to the wider industrial sphere, but which the biopharmaceutical industry is not taking advantage of. Following a face-to-face meeting in March, these were gradually whittled down to a shortlist, with two areas emerging which the Phorum intends to take forward – robotics and ILM/RTR. “The group feels there is great value in using the Phorum in ‘consortium mode’ to lower the risks and associated costs of technology adoption,” said Dawood Dassu, Phorum Lead.

Other areas that the group has identified as requiring focus over the coming months are secondary packaging and highly active/toxics in a multi-product environment.

Robotics

There has been a relatively slow take-up of robotics in the biopharmaceutical industry, particularly in fill finish, However, manufacturers are now coming to market with a variety of robots that can be used in this arena. The promise is that robotics means manufacturing becomes more agile, operations can be simplified, changeovers automated, accuracy improved and the need for human intervention, and hence errors, is removed, while the risk of contamination is greatly reduced.

Discussions have revealed that several organizations were already using robots in their fill finish areas. So now the group plans to survey their usage, understand the plans companies have for extending their usage, and collate the challenges people are facing in their operation or in justifying the spend. On the back of this, the group will look to revise the Small Flexible Filler User Requirements Specification (URS) composed in 2017/8 to include greater emphasis on robotics. This will involve significant collaboration with organizations which develop and manufacture this technology.

In-line monitoring/Real-time release (ILM/RTR)

Measuring the quality of a drug product (DP) during the manufacturing process is time-consuming involving stopping the flow of the process, taking a sample, testing it in a lab and waiting for the results. But if you can integrate this into the process a vial can effectively be cleared in real time.

Introducing ILM/RTR in fill finish is contentious, however. So, to flush out the pros and cons, an Oxford-style debate was held to discuss whether ILM could deliver adequate benefits to justify overcoming the barriers to adoption. Following a frank exchange of views, more than three-quarters of delegates (77%) voted in favor of pursuing the technology further. While the initiative is visionary, and faces multiple challenges, the consensus was that it is something that needs to happen although it is by no means a done deal.

“[At this stage], we’re not going all in… we’re making incremental progress – like an experienced poker player,” said Jason Vorhees, Principal Project Manager at Roche.

The group now plans to assemble a pathfinder group, which will use the process developed in the Technology Roadmapping Phorum to understand the required quality attributes and process control parameters in the DP process. The group will then perform a gap analysis to decide the best way to facilitate progress.

Secondary packaging

Working in a pathfinder team over the last two months, leaders and subject matter experts have agreed to work on the challenges of moving from large secondary packaging runs to small, higher value runs, including changeover times and line clearance; digital labeling and leaflets; and serialization.

Increasingly new DPs are niche, serving fewer patients, increasing production costs and making it critical to be good at short flexible runs.  The scoping exercise will continue over the summer so that the group can confirm the key areas to progress and agree the outputs they want to achieve.

Highly actives/toxics in multi-product operations 

Increasingly highly active and toxic niche market products are appearing in our product portfolios.  This is a topic that was first discussed in the Phorum five years ago but now with the growth of the membership it is easier to find a critical mass of companies keen to share and collaborate on some of the challenges these products create in production facilities, such as how do we handle these highly active products in a multi-product environment and ensure cross-contamination is not possible? How do we best conduct changeovers? And how do we continue to protect operators? Have we got the most appropriate regulations and framework in place?

To answer these questions, the workstream is set to establish a pathfinder group to identify and scope potential areas of collaboration.

For more information, contact dawood@biophorum.com.

Contact address

BioPhorum
The Gridiron Building
One Pancras Square
London
N1C 4AG

Newsletter subscribe

You can unsubscribe at any time by clicking the link in the footer of our emails. For information about our privacy practices, please visit our website.



© 2019 Biophorum Operations Group · All Rights Reserved

Registered Address: 5 Westbrook Court · 2 Sharrow Vale Road · Sheffield · S11 8YZ

Company Number 06794795 · VAT Number GB298617544

Driving progress in Cell & Gene Therapy

Now with 19 member companies and 183 subject matter experts, the BioPhorum Cell & Gene Therapy (C>) Phorum has made great strides since its formation[...]

Read More
Cell and Gene Therapy Phorum accelerates progress

The BioPhorum Cell & Gene Therapy Phorum has made significant progress since its creation in 2018 – from building networks and sharing knowledge to endorsing[...]

Read More
2018 highlights

BioPhorum’s mission has always been to make the journey for tackling industry challenges better, faster and cheaper for members. By helping you to work on[...]

Read More
Sharing ideas on forced degradation

“Forced degradation studies are an important part of the drug lifecycle process as they can inform many aspects of drug development,” said Jennifer Halley, Principal[...]

Read More
The BioPhorum and USP collaborative journey to new standards

BioPhorum and United States Pharmacopeia (USP) share a common direction – to accelerate biopharma innovation, quality and progress through collaboration.

Read More
Perfecting balanced scorecards for CDMOs

Established in March 2017, the Development Group’s Development Outsourcing effort aims to share and build guidance that will help companies make the best decisions and[...]

Read More
How well can you handle SUS changes?  Take our surveys and see

BioPhorum delivery of value from the disposables five-year plan - supplier change notifications for single-use systems

Read More
2018 highlights

BioPhorum’s mission has always been to make the journey for tackling industry challenges better, faster and cheaper for members. By helping you to work on[...]

Read More
Why leaders should go to where work is performed to learn about success, failure and risk
Read More
Hi-tech ambitions for Fill Finish

The Fill Finish Phorum has recently embarked on a series of exciting and ambitious initiatives, exploring new technologies and processes to enhance the efficiency and[...]

Read More
Companies poised to follow ARMM recommendations

The Advanced and Rapid Microbial Methods (ARMM) team set out a clear case for modernizing Environmental Monitoring (EM) in grade A settings: in summary bio-fluorescent[...]

Read More
How to achieve the ‘Goldilocks’ amount of environmental monitoring

Regulators require a risk-based approach to environmental monitoring (EM)… but they give no clear definition of what “risk-based” actually means. The aim of the Environmental[...]

Read More
The ‘how to’ guide to implementing Agile in GxP

The publication of the Guidance on the use of Agile in a GxP Environment document in 2017 was well received.It described how the use of[...]

Read More
How smart is your maintenance?

Faster. Cheaper. Smarter. All companies are under pressure to achieve more with less, not least with their maintenance programs. But while ‘faster’ and ‘cheaper’ maintenance[...]

Read More
2018 highlights

BioPhorum’s mission has always been to make the journey for tackling industry challenges better, faster and cheaper for members. By helping you to work on[...]

Read More
Supply chain, forecasting and demand planning solutions gain momentum

The relationship between suppliers and manufacturers is one of the most crucial in biopharmaceutical manufacturing. This is especially the case when forecasting and supply planning.[...]

Read More
2018 highlights

BioPhorum’s mission has always been to make the journey for tackling industry challenges better, faster and cheaper for members. By helping you to work on[...]

Read More
BioPhorum and Rx-360 pilot a joint audit model for single-use systems

BioPhorum and Rx-360 have agreed a pilot to validate the use of the Joint Audit Model in the single-use systems supply chain.

Read More
Removing the roadblocks to continuous biomanufacturing

Continuous downstream processing is increasingly seen as a feasible approach for manufacturing biologics. The industry recognises that it offers advantages over batch-based processing by:

Read More
Changing mindsets with a modular approach

Historically, manufacturers have used a ‘waterfall’ approach when designing and building their production facilities, sequentially resolving and specifying all aspects up front and in detail[...]

Read More
How do you bring technology roadmapping to life?

You use it to make change happen and that is exactly what the Phorum’s leaders did after the first edition of the Biomanufacturing Technology Roadmaps[...]

Read More
Slicing years off change implementation

As the first regulatory authority in Latin America to gain full membership of the International Council for Harmonization (ICH), the Brazilian Health Regulatory Agency (Anvisa)[...]

Read More
BioPhorum Regulatory Interaction: helping to open doors

To implement any change in the biopharmaceutical manufacturing industry it is important to engage with and collaborate with the regulators. Set up two years ago,[...]

Read More
A new way to navigate the regulatory maze of medical technology

How do you prefer to face a challenge? Fly solo or work with a team of like-minded experts? The MedTech Phorum is a new collaboration[...]

Read More
Navigating the maze of medical technology regulation: a solo voyage or a team effort?

Medical technology is a global business, generating annual revenues of over $400bn. The sector encompasses a broad range of technologies: from in-vitro diagnostics and diagnostic[...]

Read More

IaaS Cloud webinar recording play back
Read More
New BPIT guidance to align cloud services to regulatory requirements
Read More
Data Integrity and Agile Webinars to support industry response to regulators
Read More
How to validate informatics in CPV programs

The BioPhorum Continued Process Verification (CPV) and Informatics team has published a paper to support a risk-based approach for the validation of informatics systems for[...]

Read More
Continued Process Verification delivering real saving in time and money

More than 50 per cent of biopharma products on the market now have Continued Process Verification (CPV) plans in place.  Thanks to the CPV white[...]

Read More
A roadmap for the implementation of continued process verification

This article provides a roadmap draws on the content of the CPV case study to provide a step-by-step guide in a more accessible form.

Read More
How smart is your maintenance?

Faster. Cheaper. Smarter. All companies are under pressure to achieve more with less, not least with their maintenance programs. But while ‘faster’ and ‘cheaper’ maintenance[...]

Read More
Digital plant maturity model webinar replay
Read More
Digital Plant Maturity Model workstream to host webinar
Read More
New guidance available on Forecasting and Demand Planning to streamline supply chain performance
Read More
Host cell proteins poster

This poster presented at the BEBPA Conference, San Francisco builds and consolidates the information currently available in the industry for assessing process risk from Host[...]

Read More
Host cell protein risk assessment, an industry approach

Host cell protein (HCP) constitutes a significant class of process-related impurities in biological drugs.

Read More
BEBPA risk assessment workshop
Read More